Navigation Links
Oramed Pharmaceuticals Chosen to Present at the 8th Annual Israel Strategic Partner and Venture Conference on September 22, 2011
Date:9/15/2011

JERUSALEM, September 15, 2011 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (OTC BB: ORMP.OB) (http://www.oramed.com), a developer of oral delivery systems, announced today that Ehud Arbit, M.D., the Director of R&D at Oramed, is scheduled to present at the 8th Annual Israel Strategic Partner and Venture Conference. The conference will be held at the Bristol-Myers Squibb Pharmaceutical Research Institute in Princeton, NJ on September 22, 2011.  

Dr Arbit is scheduled to speak on Thursday September 22, 2011 at 4:30 p.m. ET. This conference offers Oramed the opportunity to present its strategic initiatives, updates and product pipeline to investors, strategic partners, including pharmaceutical companies, leading venture capital firms and angel investors.

For more information about the conference please visit http://www.blankrome.com/index.cfm?contentID=35&itemID=2153

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule currently in Phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research performed by top research scientists at Jerusalem's Hadassah Medical Center. Oramed's corporate and R&D headquarters are based in Jerusalem.

For more information, please visit http://www.oramed.com

SafeHarbor Statement

Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the Company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the Company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the Company to differ materially from those expressed or implied in such forward looking statements. The Company undertakes no obligation to update or revise any forward-looking statements.

Company and Investor Relations Contacts:
Oramed Pharmaceuticals
Tara Horn
Office: +1-646-240-4193
Cell: +972-54-334-4318
Email: tara@oramed.com



'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Oramed Pharmaceuticals to Hold Conference Call on August 6 to Present Results of Phase 2A Oral Insulin Capsule Clinical Trials
2. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
3. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
4. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
5. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
6. /K I L L K I L L K I L L -- Oramed Pharmaceuticals Inc./
7. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
8. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
9. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
10. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
11. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Research and Markets has announced the addition of the ... to their offering. ... The global CINV drugs market to grow at a CAGR ... Surgery Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. To calculate ...
(Date:1/18/2017)... annual growth ranging from 6% to 10%, South East Asia,s ... 22-24, 2017) serves the industry by fostering the regional discourse - Sign up ... Investment Forum ASEAN -- India strategic ... Enhanced business matchmaking program Roadshows ... ...
(Date:1/18/2017)... Jan. 18, 2017   Seno Medical Instruments, Inc. ... breast cancer through the development of an opto-acoustic (OA/US) ... Miller as SVP of Engineering. Mr. Miller previously ... FUJIFILM SonoSite, with headquarters in Bothell, Washington ... his 30-year career to the development of innovative medical ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... 18, 2017 , ... Visually learn facts and tips on ... Certain Dri. , Excessive sweating and hyperhidrosis are common conditions that occur in ... explain the seven types of hyperhidrosis. This visual creates awareness about the condition ...
(Date:1/18/2017)... Cary, NC (PRWEB) , ... January 18, 2017 , ... ... spots remain on Team V, its official endurance training and fundraising team, to compete ... the V Foundation welcomes those inspired to finish the world’s oldest annual marathon to ...
(Date:1/18/2017)... ... 18, 2017 , ... Park Agencies Insurance & Financial Services, ... and business owners in the greater Kansas City area, is joining the Lakemary ... The Lakemary Center is a comprehensive educational resource center that provides area children ...
(Date:1/18/2017)... ... January 18, 2017 , ... Michael J. ... website for its Center for Biosimilars, announced Michael J. Hennessy Associates, Inc. President ... the field of biosimilars through thought leader interaction in, live video and interactive ...
(Date:1/18/2017)... ... 2017 , ... Floundering on New Year’s resolutions? Need an excuse to get ... reset. The U.S. Apple Association agrees and recommends starting each day with apples, ... to heart disease. , The U.S. Apple Association – which represents apple growers and ...
Breaking Medicine News(10 mins):